Let’s explore the implications of this clinical achievement for Kodiak’s market position, the calculations behind its current ...
The post-pandemic bubble popped, but life sciences aren’t going anywhere. Blackstone announced Monday that it closed ...
Wave Life Sciences (WVE) stock plunges as the company interim data from an early-stage trial for WVE-007, its RNA-based ...
The U.S. Patent and Trademark Office (USPTO) on Monday held the first of three planned Patent Trial and Appeal Board ...
Galapagos (GLPG) backs Gilead’s Ouro Medicines deal, sharing $1.675B upfront and milestones, plus 20–23% royalties on gamgertamig—read more.
Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...
Wave Life Sciences (WVE) stock plunged 30% after INLIGHT Phase 1 obesity trial data revealed modest results, sparking ...
Anthropic is launching Claude for Life Sciences, a new model aimed at aiding scientific research. Through integrations with leading life sciences players, the platform will help researchers at every ...
On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results